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Summary: 42 
During early human development, the totipotent zygote differentiates into a blastocyst 43 
comprised of pluripotent epiblast cells, which form the fetus, and extra-embryonic cells that 44 
contribute to the placenta and yolk sac. Despite their fundamental biological and clinical 45 
importance, the molecular mechanisms that regulate these first cell fate decisions are unclear. 46 
Here we use CRISPR/Cas9-mediated genome editing to investigate the function of the 47 
pluripotency transcription factor OCT4 during human embryogenesis. Using an inducible 48 
human embryonic stem cell (hESC)-based system we identified the most efficient OCT4-49 
targeting single guide RNA (sgRNA). By testing homologous sgRNAs in mouse zygotes we 50 
further validated sgRNAs in vivo and optimised microinjection techniques. Using these 51 
refined methods, we then efficiently and specifically targeted OCT4 in diploid human zygotes 52 
 2 
and observed compromised blastocyst development. Transcriptomics analysis revealed that 53 
OCT4-null cells downregulated the expression of not only extra-embryonic trophectoderm 54 
genes, such as CDX2 and HAND1, but also regulators of the pluripotent epiblast, including 55 
NANOG. By contrast mouse embryos maintained the expression of orthologous genes, and 56 
blastocyst development is established, but maintenance is compromised. Altogether, we 57 
conclude that CRISPR/Cas9-mediated genome editing is a powerful method to interrogate 58 
gene function in the context of human development.  59 
 60 
Introduction  61 
Early mammalian embryogenesis is controlled by mechanisms governing the balance between 62 
pluripotency and differentiation. Expression of early lineage-specific genes varies 63 
significantly between species1-3 with implications for developmental control and stem cell 64 
derivation. However, the mechanisms patterning the human embryo are unclear, because 65 
methods to efficiently perturb gene expression of early lineage specifiers in this species have 66 
been lacking. 67 
 68 
The efficiency of genetic modification has significantly increased due to recent advances in 69 
genome editing using the CRISPR (clustered regularly interspaced, short palindromic 70 
repeat)/Cas (CRISPR-associated) system. The Streptococcus pyogenes Cas9 endonuclease is 71 
guided to homologous DNA sequences via a single-guide RNA (sgRNA) whereby it induces 72 
double strand breaks (DSBs) at the target site4. Several endogenous DNA repair mechanisms 73 
function to resolve the DSBs, including error-prone non-homologous or micro-homology 74 
mediated end joining, which can lead to insertions or deletions (indels) of nucleotides that can 75 
result in the null mutation of the target gene. CRISPR/Cas9-mediated editing has been 76 
attempted in abnormally fertilised tripronuclear and a limited number of normally fertilised 77 
human zygotes with variable success5-8. To determine if CRISPR/Cas9 can be used to 78 
understand gene function in human preimplantation development, we chose to target 79 
POU5F1, a gene encoding the developmental regulator OCT4, as a proof-of-principle. 80 
Zygotic POU5F1 is thought to be first transcribed between the 4- to 8-cell stage and OCT4 81 
protein is not detectable prior to embryo genome activation (EGA) at approximately the 8-cell 82 
stage2,3. OCT4 perturbation would be predicted to cause a clear developmental phenotype 83 
based on studies in the mouse9,10 and human embryonic stem cells (hESCs)11.  84 
 85 
By employing an inducible hESC-based system and optimising mouse zygote microinjection 86 
techniques, we identified conditions to efficiently and precisely target POU5F1. Live embryo 87 
imaging revealed that while OCT4-targeted human embryos initiate blastocyst formation, the 88 
inner cell mass (ICM) forms poorly, and embryos subsequently collapse. We demonstrated 89 
that OCT4 has an earlier role in the progression of the human blastocyst and that mutations 90 
affecting POU5F1 are correlated with the downregulation of genes associated with all three 91 
preimplantation lineages, including NANOG (epiblast), GATA2 (trophectoderm) and GATA4 92 
(primitive endoderm). By contrast, in OCT4-null mouse blastocysts, genes such as Nanog 93 
continue to be expressed in the inner cell mass. The insights gained from these investigations 94 
advance our understanding of human development and suggest that there may be distinct 95 
mechanisms of lineage specification between these species.  96 
 97 
Results 98 
 99 
Selection of a highly-efficient sgRNA targeting POU5F1 in hESCs 100 
To target POU5F1, we selected 4 sgRNAs using a standard in silico prediction tool12: two 101 
targeting the exon encoding the N-terminal domain of OCT4 (sgRNA1-1 and sgRNA1-2), one 102 
targeting the exon encoding the conserved DNA binding POU homeodomain13,14 (sgRNA2b) 103 
and one targeting the end of the POU domain and start of the C-terminal domain (sgRNA4) 104 
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(Extended Data Fig. 1a). To screen candidate sgRNAs we took advantage of hESCs as an 105 
unlimited resource that reflects the cellular context of the human preimplantation embryo. We 106 
engineered isogenic hESCs constitutively expressing the Cas9 gene, together with a 107 
tetracycline-inducible sgRNA11 (Fig. 1a), thereby allowing for comparative assessment of 108 
sgRNA activities. 109 
 110 
Cells were collected every day for 5 days for flow cytometry analysis, which revealed that 111 
induction of each of the sgRNAs in hESCs imposed remarkably different temporal effects on 112 
OCT4 protein expression (Extended Data Fig. 1b). sgRNA2b was most efficient at rapidly 113 
causing loss of OCT4 protein expression, with only 15.6% of cells retaining detectable OCT4 114 
by day 5 (d5) of induction. Immunofluorescence analysis following sgRNA2b induction 115 
confirmed the efficient knockdown of OCT4 expression (Fig. 1b, Extended Data Fig. 2a). 116 
Conversely, in hESCs induced to express sgRNAs 1-1, 1-2, or 4, 70.5%, 43.7% and 51.7% of 117 
cells retained OCT4 expression at the equivalent time-point, respectively (Extended Data Fig. 118 
1b). To determine the transcriptional consequences of OCT4 depletion, we performed qRT-119 
PCR and RNA-sequencing (RNA-seq) analysis on induced and non-induced sgRNA2b-120 
expressing hESCs (Extended Data Figs. 1c,d and 2b). sgRNA2b-induction resulted in 121 
downregulation of pluripotency genes such as NANOG, ETS1 and DPPA3 consistent with 122 
OCT4 depletion causing exit from self-renewal. Furthermore, PAX6, SOX17, SIX3, GATA2 123 
and SOX9 were upregulated following sgRNA2b-induction, suggesting that OCT4 normally 124 
restrains differentiation (Extended Data Figs. 1c,d, Extended Data Fig. 2a,b). 125 
 126 
Stereotypic POU5F1 on-target indel mutations and targeting specificity in hESCs 127 
To compare the on-target editing efficiencies and mutation spectrums induced by candidate 128 
sgRNAs, we performed a time-course genotypic analysis on cells collected across 4 days 129 
following sgRNA induction. Targeted deep sequencing of the on-target site revealed indels 130 
from as early as 24 h post-induction of sgRNA2b, but not until 48 h post-induction of 131 
sgRNAs1-1, 1-2 or 4 (Fig. 1c). sgRNA2b-induced indels most commonly comprised a 2 bp 132 
deletion upstream of the PAM site leading to a frameshift mutation and a premature stop 133 
codon (Extended Data Fig. 3), consistent with the loss of OCT4 protein expression. 134 
 135 
We evaluated putative off-target sites identified by their sequence similarity to the seed region 136 
of sgRNA2b (Extended Data Fig. 4a,b). We did not observe off-target indels in sgRNA2b-137 
induced hESCs, nor any sequence alterations above background PCR error rates observed in 138 
control hESC lines. In parallel we performed a genome-wide unbiased evaluation of off-target 139 
events using Digenome-seq (Extended Data Fig. 4c). Targeted deep sequencing across the 140 
experimentally determined putative off-target sites revealed that indels had only occurred at 141 
the on-target site (Extended Data Fig. 4d). Furthermore, we used the WebLogo program to 142 
determine the most frequent sequences associated with putative sites identified from 143 
Digenome-seq15,16 (Extended Data Fig. 4e). Deep sequencing at these sites also confirmed that 144 
no off-target events had occurred (Extended Data Fig. 4f). In all, due to both its efficient 145 
mutagenicity and high on-target specificity, sgRNA2b appeared most promising. 146 
 147 
sgRNA activity during mouse preimplantation development  148 
We used published sgRNA/Cas9 mRNA zygote microinjection conditions17 to further assess 149 
sgRNA activity and optimize microinjection methodologies in mouse zygotes. As it has been 150 
shown that OCT4-null mouse blastocysts lack expression of the primitive endoderm marker 151 
SOX17 due to a cell-autonomous requirement for FGF4/MAPK signaling9,18, we used 152 
absence of both OCT4 and SOX17 immunostaining to identify OCT4-deficient embryos (Fig. 153 
1d). This OCT4-null phenotype was observed in 54% of embryos injected with Cas9 mRNA 154 
and sgRNA2b, and in 0%, 10% or 3% of embryos injected with sgRNA1-1, sgRNA1-2 or 155 
sgRNA4, respectively (Fig. 1e). These data confirm that sgRNA2b is superior to other tested 156 
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sgRNAs at inducing null mutations in both mouse embryos and hESCs. We next interrogated 157 
a greater range of Cas9 mRNA and sgRNA concentrations to identify conditions that may 158 
enhance rates of mutagenesis (Extended Data Fig. 5a). We confirmed that the previously 159 
reported concentration of 100 ng/l Cas9 mRNA together with 50 ng/L sgRNA17 is optimal 160 
for inducing an OCT4-null phenotype. 161 
 162 
It has been suggested that microinjection of sgRNA/Cas9 ribonucleoprotein complexes may 163 
reduce mosaicism and allelic complexity by bypassing the requirement for Cas9 translation 164 
and sgRNA/Cas9 complex formation in embryos19,20. To test this, we microinjected mouse 165 
pronuclear zygotes with preassembled ribonucleoprotein complexes containing varying 166 
concentrations of Cas9 protein (20 – 200 ng/L) and sgRNA2b (20 – 100 ng/L; Fig. 1f and 167 
Extended Data Fig. 5b). Immunofluorescence analysis revealed that the sgRNA/Cas9 complex 168 
was superior to Cas9 mRNA in causing loss of both OCT4 and SOX17, and that the optimal 169 
concentration comprised 50 ng/L Cas9 protein and 25 ng/L sgRNA (Fig. 1f). Interestingly, 170 
MiSeq analysis demonstrated that 83.3% of blastocysts derived from sgRNA2b/Cas9 complex 171 
microinjections had 4 or fewer different types of indels (Fig. 1g), suggesting that editing 172 
occurred prior to, or at the 2-cell stage. By contrast, only 52.6% of sgRNA2b/Cas9 mRNA 173 
microinjected embryos exhibited this range of indels. Furthermore, a greater proportion of 174 
blastocysts formed after sgRNA2b/Cas9 mRNA microinjection had 6 or more different types 175 
of detectable indels (42.2%) compared to the sgRNA2b/Cas9 complex (8.3%). This increased 176 
mutational spectrum suggests that following Cas9 mRNA injection, DNA editing occurred 177 
between the 3- to 4-cell stage. Consistent with previous reports21, we observed a stereotypic 178 
pattern in the type of indels detected in independently targeted embryos, including the 179 
representative 28 bp deletion (Extended Data Fig. 5c), which was distinct from those induced 180 
in hESCs.  181 
 182 
In addition to lacking SOX17 and OCT4 expression, mouse embryos microinjected with the 183 
sgRNA2b/Cas9 complex recapitulated other reported OCT4-null phenotypes such as 184 
downregulation of PDGFRA, SOX7, GATA6 and GATA4 in the primitive endoderm 185 
(Extended Data Fig. 5d).  Consistent with the role of OCT4 in repressing TE genes9, the few 186 
inner cell mass (ICM) cells that could be detected in sgRNA2b/Cas9 microinjected embryos 187 
ectopically expressed CDX2 (Extended Data Fig. 5d). When plated in mouse ESC derivation 188 
conditions, these embryos failed to generate ICM outgrowths, and instead exhibited 189 
differentiation to trophoblast-like cells (Extended Data Fig. 5e). In contrast, blastocysts 190 
derived from non-injected embryos formed ICM outgrowths in most instances, as did 191 
blastocysts from embryos microinjected with Cas9 protein alone or an sgRNA/Cas9 complex 192 
targeting Dmc1 (a gene not essential for preimplantation development). Having thus 193 
determined sgRNA2b to be an efficient and specific guide capable of generating a null 194 
mutation of POU5F1/Pou5f1 in both hESCs and mouse preimplantation embryos, we next 195 
used this together with our optimized microinjection technique to target POU5F1 in human 196 
preimplantation embryos. 197 
 198 
Targeting POU5F1 in human preimplantation embryos 199 
To determine the requirement for OCT4 in human embryos, we performed CRISPR editing 200 
on thawed in vitro fertilized zygotes that were donated as surplus to infertility treatment. We 201 
microinjected 37 zygotes with the sgRNA2b/Cas9 ribonucleoprotein complex (Supplementary 202 
Video 1), and 17 zygotes with Cas9 protein alone, to control for the microinjection technique. 203 
Of the sgRNA2b/Cas9 microinjected zygotes, 30 embryos retained both pronuclei during 204 
microinjection with pronuclear fading observed approximately 6 hours later, followed by 205 
cytokinesis on average 5 hours later (Supplementary Video 2). These timings are similar to 206 
those previously published22,23 and indicate that microinjection was performed when the 207 
embryos were in S-phase of the cell cycle (Fig. 2a). Genome editing via the ribonucleoprotein 208 
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complex has been estimated to start after approximately 3 hours in vitro and persist for 12-24 209 
hours24, therefore CRISPR/Cas9-induced DSBs are likely to be formed during late S-phase, or 210 
subsequently at G2 phase. In 7 sgRNA2b/Cas9 microinjected zygotes, the pronuclei had 211 
already faded after thawing, thus they had exited S-phase and were undergoing syngamy. 212 
These embryos consequently underwent cell division approximately 3 hours after 213 
microinjection. In these embryos editing likely occurred at the G2 or M phase, or in the G1 214 
phase of the next cell cycle, at the 2-cell stage (Fig. 2a), which would promote mosaicism. 215 
 216 
Time-lapse microscopy of the embryos showed that the timings of cleavage divisions 217 
following pronuclear fading were similar between the Cas9 protein and the sgRNA2b/Cas9 218 
microinjected embryos (Fig. 2b,c). By the 8-cell stage, cleavage arrest was observed in 43% 219 
(16 out of 37) of sgRNA2b/Cas9 microinjected embryos compared to 41% (10 out of 17) 220 
Cas9 protein control embryos (Fig. 2d). As developmental arrest at the onset of EGA at the 8-221 
cell stage strongly correlates with aneuploidy in IVF embryos25, we also sought to determine 222 
embryo karyotype. We performed low-pass whole genome sequencing, which has been shown 223 
to accurately estimate gross chromosome anomalies26. We collected blastomeres from 224 
sgRNA2b/Cas9 microinjected embryos arrested up to the 8-cell stage and detected 225 
chromosomal loss or gain in 83% (5 out of 6) of embryos (Extended Data Fig. 6a), which is 226 
consistent with rates reported by preimplantation genetic screening26,27. Trophectoderm 227 
biopsies of a subset of blastocysts that developed following sgRNA2b/Cas9 microinjection 228 
determined that 60% (3 out of 5) were euploid (Fig. 2e, Extended Data Fig. 6a). The other two 229 
blastocysts exhibited karyotypic abnormalities including the loss of chromosome 16 230 
(Extended Data Fig. 6b), an abnormality frequently observed in human preimplantation 231 
embryos and thus likely to be unrelated to targeting25. In the Cas9 protein control group, 57% 232 
(4 out of 7) of blastocysts were euploid, and aneuploidies were observed in the remaining 3 233 
blastocysts, including the loss of chromosome 14 in two sibling-matched control embryos, 234 
and the gain of chromosome 15 and 18 (Fig. 2e, Extended Data Fig. 6a,b). Altogether, this 235 
suggests that CRISPR/Cas9 targeting does not increase the rates of karyotypic anomalies in 236 
human embryos. 237 
 238 
47% (8 out of 17) of Cas9 protein microinjected controls developed to the blastocyst stage, a 239 
rate equivalent to those of uninjected controls28, suggesting that the microinjection technique 240 
did not affect embryo viability (Fig. 2d). However, only 19% (7 out of 37) of sgRNA2b/Cas9 241 
protein microinjected embryos developed to the blastocyst stage, significantly fewer 242 
compared to Cas9 protein microinjected controls (Fig. 2d, P<0.05). The blastocysts that 243 
formed following sgRNA2b/Cas9 protein microinjection were of variable quality (Extended 244 
Data Fig. 6c). Although all blastocysts had a discernible blastocoel cavity, only some 245 
possessed a small compact ICM (Extended Data Fig. 6c), and all retained a thick zona 246 
pelucida, in contrast to Cas9 microinjected controls. sgRNA2b/Cas9 microinjected human 247 
embryos also went through iterative cycles of expanding and initiating blastocyst formation 248 
and then collapsing until some embryos ultimately degenerated (Supplementary Video 2 and 249 
3). Altogether, this suggests that targeting OCT4 in human embryos impacts both blastocyst 250 
viability and quality. 251 
 252 
To determine on-target editing efficiency, we performed targeted deep and/or Sanger 253 
sequencing of all cells microdissected from the sgRNA2b/Cas9 microinjected embryos 254 
arrested prior to the 8-cell stage, and found indels at the POU5F1 on-target site in 71% (5 out 255 
of 7) of embryos (Fig. 3a). The most frequently observed indels in sgRNA2b/Cas9 256 
microinjected embryos were the 2 bp and 3 bp deletions that were observed in the sgRNA2b 257 
induced hESCs (Fig. 3b, Extended Data Fig. 7a,b). This finding indicates that hESCs can be 258 
used not only to screen sgRNA efficiency, but also to predict the in vivo mutation spectrum 259 
induced by CRISPR/Cas9-mediated genome editing. We also detected larger POU5F1 260 
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deletions in the human embryos compared to hESCs, similar to our observations in mouse 261 
embryos (Fig. 3b, Extended Data Fig. 7a,b). Furthermore, targeted deep and/or Sanger 262 
sequencing in edited cells demonstrated that off-target mutations were undetectable above 263 
background PCR error rates, further confirming the specificity of the sgRNA (Extended Data 264 
Fig. 7c,d). 265 
 266 
We next assessed mutational signatures in more developmentally advanced embryos, after 267 
EGA. Interestingly, we confirmed that on-target editing had occurred in 8 out of 8 268 
sgRNA2b/Cas9 microinjected embryos analysed from the 8-cell to the blastocyst stage. 269 
However, invariably these embryos all retained wild-type copies of the POU5F1 allele in at 270 
least one cell (Fig. 3a). In sgRNA2b/Cas9 microinjected human embryos, OCT4 protein 271 
expression was downregulated in most cleavage-stage cells and undetectable above 272 
background in others, confirming high efficiency of editing (Fig. 3c; Extended Data Fig. 8a). 273 
However, we were able to identify at least one cell that had nuclear OCT4 staining above 274 
background levels (Fig. 3c; Extended Data Fig. 8a). Moreover, despite a significant reduction 275 
in cell number, blastocyst-stage embryos also retained OCT4 expression in a subset of cells 276 
(Fig. 3d,e Extended Data Fig. 8b,c). These findings suggest that POU5F1 targeting efficiency 277 
is high, and that only embryos with partial OCT4 expression are able to progress to the 278 
blastocyst stage. 279 
 280 
To determine if there is a high degree of editing in embryos prior to the onset of OCT4 281 
expression, we microinjected 4 additional human embryos with the sgRNA2b/Cas9 complex 282 
and stopped their development prior to the 8-cell stage. 100% (4 out of 4) of these embryos 283 
had detectable indels, with two embryos lacking wild-type POU5F1 alleles (Fig. 3a). In one 284 
embryo editing occurred in all blastomeres, although one blastomere retained one copy of the 285 
wild-type allele. In another embryo, while 4 out of 5 blastomeres had been edited, one 286 
blastomere retained both copies of the wild-type allele. Together with the cleavage arrested 287 
embryos above, this demonstrates that in 45% (5 out of 11) of cleavage stage embryos (either 288 
stopped or developmentally arrested), all of the cells analysed from each embryo had no 289 
detectable POU5F1 wild-type alleles, indicating high rates of editing. Altogether these data 290 
suggest an unexpectedly earlier function for OCT4 in humans compared to mice, prior to 291 
blastocyst formation. 292 
 293 
Loss of OCT4 in human embryos is associated with mis-expression of genes associated 294 
with the three lineages in the blastocyst 295 
To determine globally which genes might be affected by the loss of OCT4, we microdissected 296 
single cells from microinjected embryos at the blastocyst stage. We adapted a method to 297 
isolate both RNA and DNA from single cells29 in order to perform RNA-seq and targeted 298 
deep or Sanger sequencing of on-target and putative off-target sites. Principal component 299 
analysis showed that cells from sgRNA2b/Cas9 microinjected human blastocysts clustered 300 
distinctly from those derived from Cas9 protein microinjected controls (Fig. 4a). Intriguingly, 301 
the cluster from sgRNA2b/Cas9 microinjected embryos contained not only cells that were 302 
genotypically knockout for POU5F1, but also those that were wild-type or heterozygous for 303 
POU5F1. This finding suggests that loss of POU5F1 may impose non-cell autonomous 304 
effects on gene expression in neighbouring wild-type or heterozygous cells. 305 
 306 
Differential gene expression analysis indicated that genes most highly mis-expressed in the 307 
sgRNA2b/Cas9 targeted human blastocysts compared to the Cas9 protein controls included 308 
those that we previously identified as highly enriched in the epiblast, including NANOG, 309 
KLF17, DPPA5, ETV4, TDGF1, and VENTX (Extended Data Fig. 9a, Supplementary Table 310 
1). Immunofluorescence analysis confirmed that even in cells retaining OCT4, the expression 311 
of NANOG was absent (Fig. 4b, Extended Data Fig. 8c). In striking contrast, OCT4-null 312 
 7 
mouse blastocysts maintained Nanog expression in the ICM (Fig. 4b, Extended Data Fig. 313 
8d,e), as previously reported9,18.   314 
 315 
In OCT4-null cells several trophectoderm-associated genes were also significantly 316 
downregulated, including CDX2, HAND1, DLX3, TEAD3, PLAC8 and GATA2 (Extended 317 
Data Fig. 9a, Supplementary Table 1). We confirmed loss of GATA2 protein expression in 318 
human sgRNA2b/Cas9 protein injected embryos (Fig. 4c, Extended Data Fig. 8f). Coupled 319 
with the failure to maintain a fully expanded blastocyst, this finding suggests that the integrity 320 
of the trophectoderm may be compromised in OCT4-targeted embryos. To further 321 
characterize this, we performed immunofluorescence analysis for ZO-1, which incorporates 322 
into tight junctions during trophectoderm formation. In sgRNA2b/Cas9 targeted human 323 
blastocysts, ZO-1 expression was interrupted, patchy and diffuse compared to the uniform 324 
network-like distribution in uninjected control embryos (Fig. 4d). This is in contrast to mouse 325 
OCT4-null embryos, where expression of trophectoderm markers such as Cdx2, Hand1 and 326 
Gata3 are upregulated9.  327 
 328 
Additionally, primitive endoderm markers such as GATA4 were downregulated in 329 
sgRNA2b/Cas9 microinjected embryos compared to Cas9 protein controls. 330 
Immunofluorescence analysis suggested that SOX17 protein expression was also 331 
downregulated (Fig. 3d, Extended Data Fig. 8b). Moreover, we were surprised to observe 332 
ectopic expression of PAX6 in some cells from sgRNA2b/Cas9 edited human blastocysts 333 
(Extended Data Fig. 9a, Supplementary Table 1). The lack of expression of genes associated 334 
with all three lineages in the blastocyst suggests that OCT4-targeted embryos either failed to 335 
initiate the expression of these genes or downregulated their expression as development 336 
progressed. To determine whether the gene expression patterns in OCT4-targeted cells more 337 
closely resemble cells from earlier stages of human development, we integrated our data with 338 
a previously published dataset comprising all stages of human preimplantation 339 
development3,30 (Fig. 4e, Extended Data Fig. 9b). This revealed that while cells from OCT4-340 
targeted embryo were progressing towards the transcriptional state of the blastocyst, they 341 
were more dispersed and heterogeneous in their gene expression. Altogether, our data 342 
suggests that the integrity of the human blastocyst is compromised as a consequence of OCT4 343 
downregulation. As a result, all lineages are negatively affected, pointing to a functional role 344 
for OCT4 in early human development. 345 
 346 
 347 
Discussion 348 
CRISPR/Cas9-mediated genome editing represents a transformative method to evaluate the 349 
function of putative regulators of human preimplantation development. We demonstrate the 350 
importance of initially screening sgRNA efficiencies and mutagenic patterns prior to targeting 351 
in human embryos, as sgRNAs were not equivalently efficient in inducing POU5F1-null 352 
mutations despite scoring highly by in silico predictions. We identify different consequences 353 
of OCT4 loss on human versus mouse embryos, consistent with other differences reported 354 
between these species. For example, pharmacological inhibition of FGF and downstream 355 
ERK signaling leads to ectopic expression of pluripotency factors in the mouse, but not the 356 
human at equivalent stages31,32. 357 
 358 
Surprisingly, our data suggests OCT4 may be required earlier in human development than it is 359 
in mice, for instance during the cleavage or morula stages, when OCT4 expression is initiated 360 
(Fig. 4f). As the mouse maternal/zygotic Pou5f1-null mutation phenocopies the zygotic-null 361 
mutation9, it is unlikely that persistence of maternal transcripts or proteins compensates for 362 
the loss of OCT4 expression, and any additional compensatory mechanisms that may be 363 
present in the mouse do not appear to be conserved in the regulation of human development. 364 
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The mis-expression of genes associated with all three blastocyst lineages further suggests that 365 
OCT4 may have an essential function prior to this stage. In the future, it would be informative 366 
to determine whether OCT4 mutation leads to changes in gene expression prior to the 367 
blastocyst stage, which may explain the failure of blastocyst development. Alternatively, 368 
inducing POU5F1-null mutations in human embryos slightly later in development, following 369 
the onset of EGA, may bypass its earlier critical role and thereby delineate its function in the 370 
fully formed blastocyst.  371 
 372 
Significantly, CRISPR/Cas9-mediated genome editing does not appear to increase genomic 373 
instability or developmental arrest prior to EGA, suggesting that this method may be used to 374 
understand the function of other putative lineage specifiers. In future, a number of adaptations 375 
may provide further advantages. Co-injection of the CRISPR/Cas9 components with sperm 376 
during intracytoplasmic sperm injection33 may allow more time for targeting prior to the first 377 
cell division, further increasing editing efficiency. Indeed, this approach has been used 378 
recently in human embryos8. Introducing multiple sgRNAs may also increase targeting 379 
efficiency, but may also increase the risk of off-target mutations. Alternatively, introducing 380 
the CRISPR/Cas9 components alongside a donor oligonucleotide complementary to the target 381 
locus and harboring a premature stop codon, should favor the generation of null mutations via 382 
homology directed repair. This approach may not be straightforward given recent attempts to 383 
correct an abnormal paternal gene variant were reported to use the maternal allele for HDR 384 
rather than an introduced template8. Targeting genes not essential for, or with a later or more 385 
specific role in pre-implantation development will also inform our interpretation of the OCT4 386 
phenotype. At present, we cannot be certain that the early developmental arrest is associated 387 
with the loss of OCT4 rather than some non-specific effect of injecting both Cas9 and the 388 
sgRNA, as opposed to the Cas9 alone. However, the only other study to date using genome 389 
editing with human embryos that showed development beyond 8-cell stages, where a non-390 
essential gene was targeted, showed normal blastocyst formation at rates similar to controls8. 391 
This suggests that the effects we see here are due to loss of OCT4. Altogether we developed 392 
an optimized approach to target OCT4 in human embryos thus revealing a distinct function 393 
compared to the mouse. This proof of principle lays out a framework for future investigations 394 
that could transform our understanding of human biology, thereby leading to improvements in 395 
the establishment and therapeutic use of stem cells and in IVF treatments. 396 
 397 
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Figure Legends 432 
Figure 1: Screening sgRNAs targeting OCT4 in optimised inducible CRISPR/Cas9 433 
knockout human embryonic stem cells (hESCs) and mouse embryos. 434 
a, Schematic of the strategy used to induce sgRNA expression in hESCs. The CAG promoter 435 
drives constitutive expression of the Cas9 gene as well as the tetracycline-responsive 436 
repressor (tetR). The inducible H1-TO promoter drives expression of each sgRNA in the 437 
presence of tetracycline (TET). The two transgenic cassettes are each targeted to one of the 438 
AAVS1 genomic safe harbour loci using zinc-finger nucleases (ZFN). (TO: tetracycline-439 
responsive operator).  440 
 441 
b, Immunofluorescence analysis of OCT4 (red) or PAX6 (green) and DAPI nuclear staining 442 
(blue) expression in hESCs after 4 days of sgRNA2b induction (+Tet). Scale bars, 100 m. 443 
 444 
c, Quantification of indel mutations detected at each sgRNA on-target site. One-way ANOVA 445 
compared to uninduced hESCs. *P<0.05; **P<0.01. 446 
 447 
d, Immunofluorescence analysis for OCT4 (red), SOX17 (green) and DAPI nuclear staining 448 
(blue) in control, OCT4-null or mosaic mouse blastocysts 4 days following zygote 449 
microinjection. Scale bar, 100 m. 450 
 451 
e, Quantification of proportions of OCT4-null, mosaic or wild-type mouse blastocysts 452 
following microinjection of Cas9 mRNA plus sgRNA1-1, sgRNA1-2, sgRNA2b, or sgRNA4 453 
or uninjected controls. Chi-squared test. Data are mean ± s.d. *P<0.05; **P<0.01; 454 
****P<0.0001. 455 
 456 
f, Quantification of proportions of OCT4-null, mosaic or wild-type mouse blastocysts 457 
following microinjection of the sgRNA2b/Cas9 ribonucleoprotein complex concentrations 458 
indicated. Chi-squared test. Data are mean ± s.d. ****P<0.0001. 459 
 460 
g, Comparison of mutation spectrums after targeting mouse embryos with sgRNA2b plus 461 
Cas9 mRNA or protein. Data are the proportion of unique indels observed. Chi-squared test. 462 
****P<0.0001 463 
 464 
Figure 2: The developmental potential of human embryos following CRISPR/Cas9-465 
mediated genome editing. 466 
a, Schematic of the first cell division in human embryos and time of microinjection. (PN, 467 
pronuclei; PNF, pronuclear fading). 468 
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 469 
b, Representative human embryo at each developmental stage analysed. (SC, start of 470 
cavitation; SB, start of blastocyst formation; B, blastocyst). 471 
 472 
c, Morphokinetic analysis of human development after microinjection. Non-parametric two-473 
tailed Kolmogorov-Smirnov test; ns, not significant. 474 
 475 
d, Kaplan–Meier survival curve of human embryos following microinjection of Cas9 protein 476 
or sgRNA2b/Cas9 ribonucleoprotein complex. Zygotic POU5F1 expression is initiated 477 
between the 4- to 8-cell stage. Chi-squared test. *P < 0.05. 478 
 479 
e, Karyotype analysis by whole genome sequencing of human blastocysts following 480 
microinjection of Cas9 protein or sgRNA2b/Cas9 ribonucleoprotein complex. Representative 481 
karyotypically normal embryos are shown. 482 
 483 
Figure 3: Genotypic characterisation of OCT4-targeted human embryos. 484 
a, Proportion of POU5F1-null, heterozygous or wild-type cells in each human embryo. The 485 
number of cells analysed is indicated. Embryos 2, 5, 7 and 8 were microinjected with Cas9 486 
protein as a control. All other embryos were microinjected with the sgRNA2b/Cas9 487 
ribonucleoprotein complex. The development of some embryos was stopped and they were 488 
removed from culture for analysis, while others were analysed following cleavage arrest. 489 
 490 
b, The type and relative proportion of indel mutations observed compared to all observable 491 
indel mutations within each human embryo.  492 
 493 
c, Immunofluorescence analysis for OCT4 (green), and DAPI nuclear staining (blue) in an 494 
uninjected control cleavage stage human embryo or an embryo that developed following 495 
sgRNA2b/Cas9 ribonucleoprotein complex microinjection (n = 5). Confocal z-section. Arrow, 496 
OCT4 expressing cell. Scale bar, 100 m. 497 
 498 
d, Immunofluorescence analysis for OCT4 (green), SOX17 (red) and DAPI nuclear staining 499 
(blue) in an uninjected control human blastocyst (n = 3) or a blastocyst that developed 500 
following sgRNA2b/Cas9 ribonucleoprotein complex microinjection (n = 3). Confocal z-501 
section. Scale bar, 100 m. 502 
 503 
e, Quantification of the number of DAPI or OCT4 positive nuclei in uninjected control human 504 
blastocysts (n = 3) compared to blastocysts that developed following sgRNA2b/Cas9 505 
ribonucleoprotein complex microinjection (n = 5). One-tailed t-test. **P < 0.01; ***P < 0.001. 506 
 507 
Figure 4: Phenotypic characterisation of OCT4 targeted human embryos. 508 
a, Principal component analysis of single-cell RNA-seq data showing comparisons between 509 
the cells from human blastocysts that developed following microinjection of the 510 
sgRNA2b/Cas9 ribonucleoprotein complex (filled shapes) compared to Cas9 protein 511 
microinjected controls (unfilled shapes). The genotype of each cell is distinguished by colour. 512 
5 samples failed repeated genotyping but the RNA quality is good and these are listed as 513 
Unknown. Each data point represents a single cell. 514 
 515 
b, Immunofluorescence analysis for OCT4 (green), NANOG (red) and DAPI nuclear staining 516 
(blue) in a human or a mouse uninjected control blastocyst or a blastocyst that developed 517 
following sgRNA2b/Cas9 ribonucleoprotein complex microinjection (mouse: n = 7; human: n 518 
= 3). Confocal z-section. Scale bar, 100 m. 519 
 520 
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c, Immunofluorescence analysis for OCT4 (green), GATA2 (magenta) and DAPI nuclear 521 
staining (blue) in an uninjected control human blastocyst (n = 3) or in a blastocyst that 522 
developed following sgRNA2b/Cas9 ribonucleoprotein complex microinjection (n = 3). 523 
Confocal projection. Scale bar, 100 m. 524 
 525 
d, Immunofluorescence analysis for OCT4 (green), ZO-1 (magenta) and DAPI nuclear 526 
staining (blue) in an uninjected control human blastocyst (n = 2) or in a blastocyst that 527 
developed following sgRNA2b/Cas9 ribonucleoprotein complex microinjection (n = 2). 528 
Confocal projection. Scale bar, 100 m. 529 
 530 
e, Principal component analysis of a previously published human single-cell RNA-seq 531 
dataset30 integrated with the data from the Cas9 protein control and the sgRNA2b/Cas9 532 
ribonucleoprotein (RNP) microinjected embryos. Each point represents a single cell. 533 
 534 
f, Diagram summarising the observations made in the study and their relationship to the onset 535 
of zygotic POU5F1 expression. 536 
 537 
 538 
 539 
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 629 
Extended Data Figure Legends 630 
 631 
Extended Data Figure 1: POU5F1 targeting and comparison of sgRNAs 632 
a, Schematic representation of the human POU5F1/OCT4 locus and sgRNA targeting sites. 633 
The location (not to scale) and sequences of the sgRNAs tested are shown and the 634 
protospacer-adjacent motif (PAM) sequences are underlined and in red font. Sequences within 635 
the exons are in uppercase and introns are in lowercase. The mouse sgRNA sequences are 636 
shown below. The exons encoding the N-terminal domain (NTD), POU DNA binding domain 637 
or the C-terminal domain (CTD) are indicated. 638 
 639 
b, Representative flow cytometry analysis quantifying OCT4 expression in hESCs induced to 640 
express each sgRNA over 5 days compared to uninduced controls. The percentage of OCT4 641 
protein expression is shown. 642 
 643 
c, qRT-PCR analysis after 4 days of sgRNA induction. Relative expression reflected as fold 644 
difference over uninduced cells normalised to GAPDH. Data points and mean for all samples 645 
are shown:  n = 2 sgRNA1-1 clones; n = 3, sgRNA 1-2, 2b or 4 clones, representative of two 646 
independent experiments and ± s.e.m. where there are three samples. Two-way ANOVA. 647 
*P<0.05; **P<0.01; ***P<0.001; ****P<0.0001. 648 
 649 
d, Heat maps of selected genes showing unsupervised hierarchical clustering of uninduced 650 
and sgRNA2b-induced hESCs. Normalised RNA-seq expression levels are plotted on a high-651 
to-low scale (purple-white-green). 652 
 653 
 654 
Extended Data Figure 2: Further characterisation of sgRNA2b-induced hESCs. 655 
a, hESCs induced to express sgRNA2b for 4 days (+Tet) in chemically defined media with 656 
activin A and FGF2 (CDM/AF) compared to uninduced controls (No Tet). 657 
Immunofluorescence analysis for pluripotency markers OCT4, NANOG and SOX2 or 658 
markers associated with differentiation to early derivatives of the germ layers (SOX1-659 
expressing ectoderm cells or SOX17-expressing endoderm cells). DAPI nuclear staining 660 
(blue) is shown. Scale bar, 400 m. 661 
 662 
b, qRT-PCR analysis for selected genes associated with either pluripotency or differentiation 663 
to derivatives of the germ layers in hESCs induced to express each of the sgRNA for 4 days. 664 
Relative expression reflected as fold difference over wild-type hESCs and normalised to 665 
PBGD. Data points and mean for all samples are shown:  n = 2 sgRNA1-1 clones; n = 3, 666 
sgRNA 1-2, 2b or 4 clones, representative of two independent experiments and ± s.e.m. where 667 
there are three samples. Two-way ANOVA. *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001, ns, 668 
not significant.  669 
 670 
Extended Data Figure 3: On-target mutation spectrum in hESCs induced to express 671 
sgRNA1-1, sgRNA1-2, sgRNA2b or sgRNA4. 672 
Shown are frequent types of indel mutations and corresponding sequences observed in hESCs 673 
induced to express sgRNA1-1, sgRNA1-2, sgRNA2b or sgRNA4. The cells were induced to 674 
express each sgRNA for 4 days and the data shown is representative of the type of indel 675 
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mutations observed in other clonal lines (n = 2 sgRNA1-1 clones; n = 3, sgRNA 1-2, 2b or 4 676 
clones) and across time (from 1 up to 4 days following induction of each sgRNA). 677 
 678 
Extended Data Figure 4: Off-target analysis of sgRNA2b-induced hESCs. 679 
a, The POU5F1 sgRNA2b 12 bp seed sequence is highlighted in green and the NGG PAM 680 
sequence in red. In black are the nucleotide sequences 5’ to the sgRNA seed sequence. 7 681 
putative off-target sequences and associated genes are shown including POU5F1 682 
pseudogenes. In orange are the nucleotides that differ from the sgRNA2b sequence. 683 
 684 
b, Percentage of indel mutations detected at putative off-target sites in hESCs 4 days 685 
following tetracycline induction of sgRNA2b compared to uninduced controls. Data are 686 
percentages of indels detected in the cell lines at each of the sites indicated. Comparisons 687 
made between three clonal hESC lines induced to express sgRNA2b versus uninduced 688 
controls. The percentage of indel mutations induced at the on-target site were significant 689 
while all other sites were not significantly different. Two-way ANOVA. ***P<0.001. 690 
 691 
c, Digenome-seq results displayed as a genome-wide circos plot. The height of the peak 692 
corresponds to the DNA cleavage score. The red arrow points to the POU5F1 locus on 693 
chromosome 6. 694 
 695 
d, Percentage of indel mutations observed in sgRNA2b-induced hESCs and in wild-type H9 696 
control cells at each locus following targeted deep sequencing of putative off-target sites 697 
identified by Digenome-seq. 698 
 699 
e, Off-target candidate nucleotides displayed as sequence logos using the WebLogo program. 700 
 701 
f, Percentage of indel mutations observed in sgRNA2b-induced hESCs and in wild-type H9 702 
control cells following targeted deep sequencing of putative off-target sites determined by 703 
WebLogo sequence homology. 704 
 705 
Extended Data Figure 5: Assessing a range of Cas9 and sgRNA combinations for 706 
microinjection into mouse pronuclear zygotes. 707 
Additional conditions were tested in mouse embryos microinjected with the sgRNA2b either  708 
a, plus Cas9 mRNA or  709 
 710 
b, as a complex with the Cas9 protein at the ratios indicated. Quantification was performed on 711 
the proportion of mouse embryos at the blastocyst stage that are phenotypically null (loss of 712 
OCT4 and SOX17 protein expression), mosaic/heterozygous (partial OCT4 and/or SOX17 713 
expression) or uninjected (strong OCT4 and SOX17 expression). Data are mean ± s.d. and 714 
comparisons made between the percentage of OCT4-null embryos observed versus wild-type 715 
uninjected control embryos. Chi-squared test. *P<0.05; ***P<0.001; ****P<0.0001. 716 
 717 
c, The type of indel mutations detected in mouse embryos microinjected with the 718 
sgRNA2b/Cas9 ribonucleoprotein complex. The sgRNA sequence is boxed and the NGG 719 
PAM site underlined. Dash, deletion position. 720 
 721 
d, Further characterization of mouse embryos microinjected with sgRNA2b/Cas9 722 
ribonucleoprotein complex compared to uninjected control blastocysts. Immunofluorescence 723 
analysis for markers of the trophectoderm (CDX2) or primitive endoderm (GATA4, GATA6, 724 
PDGFRA and SOX7) lineages together with DAPI nuclear staining. Confocal z-section. Scale 725 
bar, 100 m. 726 
 727 
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e, Quantification of blastocyst inner cell mass (ICM) or trophoblast outgrowths in mouse 728 
embryonic stem cell derivation conditions. Uninjected, Cas9-injected or Cas9 plus Dmc1 729 
sgRNA (targeting a gene not essential for preimplantation development) were used as 730 
controls. Comparisons were made to blastocysts that developed following sgRNA2b/Cas9 731 
ribonucleoprotein microinjection. Two-tailed t-test. *P<0.05. 732 
 733 
Extended Data Figure 6: Further assessing human embryo quality. 734 
a, Karyotype analysis following whole genome sequencing of either single blastomeres or 735 
trophectoderm biopsies. Multiple biopies were analysed from embryos C8, C12 and C16. 736 
Analysis was also performed on blastocysts that developed following microinjection of Cas9. 737 
The type of chromosome gains and losses are indicated. 738 
 739 
b, Representative karyotype analysis by whole genome sequencing of human blastocysts. A 740 
representative graph indicating aneuploidy in embryos following either Cas9 protein or 741 
sgRNA2b/Cas9 ribonucleoprotein complex microinjection. 742 
 743 
c, Phase-contrast images of blastocysts that developed following microinjection of the 744 
sgRNA2b/Cas9 ribonucleoprotein complex compared to Cas9 protein injected controls. White 745 
arrows point to the presumptive inner cell mass and a black arrow to a representative zona 746 
pelucida. 747 
 748 
Extended Data Figure 7: Evaluating on-target and putative off-target mutations in 749 
human embryo cells. 750 
a, The type and relative proportion of indel mutations observed compared to all observable 751 
indel mutations within each human embryo. 752 
 753 
b, Quantification of indels by TIDE analysis. Representative plots and Sanger sequencing 754 
chromatograms are shown from OCT4-null, heterozygous and wild-type human cells. 755 
 756 
c, Percentage of indel mutations detected at the sgRNA2b on-target site and putative off-target 757 
sites in single cells microdissected from Cas9 protein microinjected control blastocysts or 758 
blastocysts that developed following sgRNA2b/Cas9 ribonucleoprotein complex 759 
microinjection. Putative off-target sites were evaluated in cells that were previously 760 
determined to be OCT4-null (green), heterozygous (orange) or wild-type (blue) along with 761 
samples from Cas9 protein microinjected embryos (red). Three representative examples are 762 
shown from each group. 763 
 764 
d, Sanger sequencing chromatograms from OCT4-null single cells collected from human 765 
blastocysts that developed following sgRNA2b/Cas9 ribonucleoprotein complex 766 
microinjections. The chromatograms exemplify the sequence detected in all of the other 767 
samples analysed. Underlined is the sequence of the putative off-target site. 768 
 769 
Extended Data Figure 8: Phenotypic characterisation of OCT4-targeted embryos. 770 
a, Immunofluorescence analysis for OCT4 (green) and DAPI nuclear staining (blue) in human 771 
cleavage stage embryos following sgRNA2b/Cas9 ribonucleoprotein complex microinjection 772 
(n = 5). Confocal z-section. Arrow, OCT4 expressing cell. Scale bar, 100 m. 773 
 774 
b, Immunofluorescence analysis for OCT4 (green), SOX17 (red) and DAPI nuclear staining 775 
(blue) in an uninjected control blastocyst (n = 3) or a human blastocyst that developed 776 
following sgRNA2b/Cas9 ribonucleoprotein complex microinjection (n = 3). Confocal z-777 
section. Scale bar, 100 m. 778 
 779 
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c,d Immunofluorescence analysis for OCT4 (green), NANOG (red) and DAPI nuclear 780 
staining (blue) in (c) a human blastocyst that developed following sgRNA2b/Cas9 781 
ribonucleoprotein complex microinjection (n = 3) or (d) in a mouse uninjected control 782 
blastocyst or in blastocysts that developed following sgRNA2b/Cas9 ribonucleoprotein 783 
complex microinjection (n = 7). Confocal z-section. Scale bar, 100 m. 784 
 785 
g, Quantification of NANOG and OCT4 expression in mouse uninjected control blastocysts (n 786 
= 5) or in blastocysts that developed following sgRNA2b/Cas9 ribonucleoprotein complex 787 
microinjection (n = 7). One-tailed t-test. **P<0.01. 788 
 789 
h, Immunofluorescence analysis for GATA2 (green) and DAPI nuclear staining (blue) in a 790 
human blastocyst that developed following sgRNA2b/Cas9 ribonucleoprotein complex 791 
microinjection (n = 3). Confocal projection. Scale bar, 100 m. 792 
 793 
Extended Data Figure 9: 794 
a, Hierarchical clustering and heat map of a selection of genes following single cell RNA-seq 795 
analysis of human embryos. Embryos C8, C9, C12 and C16 (samples denoted in orange font) 796 
were targeted with the sgRNA2b/Cas9 ribonucleoprotein complex. Embryos 2, 5, 7 and 8 797 
were microinjected with Cas9 protein as a control. An uninjected control reference dataset 798 
labelled PE (primitive endoderm cells), EPI (epiblast cells) or TE (trophectoderm cells) is 799 
included3. Control cells clustered according to lineage and are indicated with the coloured 800 
bars: red = PE, green = EPI and blue = TE. Grey bar highlights the samples that have low 801 
expression of markers of each of the lineages shown. The genotype of the samples are noted 802 
as POU5F1 wild-type: WT, heterozygous: Het, or knockout: KO cells. 5 samples failed 803 
repeated genotyping but the RNA quality is good and these are listed as X. Normalised 804 
expression levels are plotted on a high-low scale (purple-white-green). 805 
 806 
b,c Principal component analysis of a previously published human single-cell RNA-seq 807 
dataset30 integrated with the data from the Cas9 protein control and the sgRNA2b/Cas9 808 
ribonucleoprotein (RNP) microinjected embryos. Each point represents a single cell. Data 809 
were plotted along the (b) second and third or the (c) first and third principal components. 810 
 811 
Extended Data Figure 10: Reagents list 812 
a, Oligonucleotides used for cloning, MiSeq or qRT-PCR analysis 813 
 814 
b, Antibodies used for immunofluorescence and flow cytometry analysis 815 
 816 
 817 
METHODS 818 
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(http://www.hfea.gov.uk/docs/07032016_Currently_licenced_research_projects.pdf) and the 823 
Health Research Authority’s Research Ethics Committee (Cambridge Central reference 824 
number 16/EE/0067).  825 
 826 
The process of approval entailed independent peer review along with approval from both the 827 
HFEA Executive Licensing Panel (8 members of the Authority) and the Executive 828 
Committees, which is composed of 5 members including members of the lay public. Our 829 
research is compliant with the HFEA Code of Practice and has undergone independent 830 
inspections by the HFEA since the licence was granted. The Research Ethics Committee is 831 
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comprised of 12 individuals including members of the lay public. Patient consent was 832 
obtained from Bourn Hall Clinic. 833 
 834 
Informed consent was obtained from all couples that donated spare embryos following IVF 835 
treatment. Before giving consent, people donating embryos were provided with all of the 836 
necessary information about the research project, an opportunity to receive counselling and 837 
the conditions that apply within the licence and the HFEA Code of Practice. Specifically, 838 
patients signed a consent form authorising the use of genome editing techniques including 839 
CRISPR/Cas9 on donated embryos. Donors were informed that after the embryos have been 840 
genetically modified their development will be stopped prior to 14 days post-fertilisation and 841 
that subsequent biochemical and genetic studies would be performed. Informed consent was 842 
also obtained from donors for all the results of these studies to be published in scientific 843 
journals.  No financial inducements are offered for donation. The patient information sheets 844 
and consent document provided to patients are publicly available 845 
(https://www.crick.ac.uk/research/a-z-researchers/researchers-k-o/kathy-niakan/hfea-licence/). 846 
Embryos surplus to the patient’s IVF treatment were donated cryopreserved and were 847 
transferred to the Francis Crick Institute where they were thawed and used in the research 848 
project. 849 
 850 
Power analysis 851 
The R statistical package pwr was used to determine the number of human embryos required 852 
to determine the function of OCT4 compared to microinjected controls. A two-sample t-test 853 
was performed to a significance level of P<0.05. The effect size was 0.8 which assumes an 854 
observable difference between the CRISPR injected and control embryos. The sample size 855 
was estimated to be 25 CRISPR-targeted embryos. 856 
 857 
sgRNA design to target POU5F1 858 
So as not to lower the targeting efficiency, we determined whether the sgRNAs targeted 859 
polymorphic regions of the human genome. Most sgRNA had a single nucleotide 860 
polymorphism (SNP) frequency of less than 0.1% in the human population, with the 861 
exception of the sgRNA targeting exon 4, which had a SNP frequency of 32% within the 862 
sgRNA target sequence as determined by the 1000 genomes project34. We retained this 863 
sgRNA as it had the highest in silico score and overlapped with a site that has been previously 864 
shown in complementarity studies to be functionally required for pluripotency, suggesting 865 
that even an in-frame deletion would render a loss of function in the gene 13. We also favoured 866 
the use of sgRNAs with sequence conservation of the PAM and sgRNA seed sequence 867 
(approximately 12bp region proximal to the PAM sequence) that would allow us to determine 868 
efficiency in mouse embryos. In the case of high-scoring sgRNAs targeting exon 2d, there is 869 
no mouse equivalent sgRNA sequence that we could evaluate, and for exon 3, we could not 870 
design sgRNAs where the predicted cut site would be within the exon; these options were 871 
therefore excluded. 872 
 873 
sgRNA production and ribonucleoprotein preparation 874 
sgRNAs were prepared as previously described35.  The sgRNA was cloned into the bicistronic 875 
expression vector px330 (Addgene; 4223036) using the Bbs1 restriction site. The sgRNA 876 
sequence from the correctly targeted px330 vector was amplified using the Q5 hot start high 877 
fidelity DNA polymerase (NEB; M0493) and the PCR product was in vitro transcribed using 878 
the MEGAshortscript T7 kit (ThermoFisher Scientific; AM1354) and purified using the Zymo 879 
RNA Clean & Concentrator columns (Zymo Research; R1017) The sgRNA and Cas9 mRNA 880 
(TriLink Biotechnologies; L61256) and recombinant Cas9 protein (Toolgen; TGEN CP1) 881 
were individually re-suspended in RNase-free water, aliquoted and stored at -80°C until use. 882 
Prior to injection the ribonucleoprotein complex was prepared by centrifuging the Cas9 883 
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protein for 1 min at 14,000 RPM at 4°C and transferring the supernatant to a fresh tube 884 
containing the sgRNA. This was incubated at 37°C for 15 min, pulse spun and transferred to a 885 
fresh tube for microinjection. 886 
 887 
Mouse zygote collection 888 
Four to eight-week-old (C57BL6 x CBA) F1 female mice were super-ovulated using injection 889 
of 5 IU of pregnant mare serum gonadotrophin (PMSG; Sigma-Aldrich). 48 h post PMSG, 5 890 
IU of human chorionic gonadotrophin (HCG; Sigma-Aldrich) was administered. 891 
Superovulated females were set up for mating with eight-week-old or older (C57BL6 x CBA) 892 
F1 males. Mice were maintained on a 12 h light/dark cycle. Mouse zygotes were isolated in 893 
Global total with HEPES (LifeGlobal; LGTH-100) under mineral oil (Origio; ART-4008-5P) 894 
and cumulus cells were removed with hyaluronidase (Sigma-Aldrich; H4272). All animal 895 
research was performed in compliance with the UK Home Office Licence Number 70/8560. 896 
 897 
Human embryo thaw 898 
Human zygotes were thawed using Quinn’s Advantage thaw kit (Origio; ART-8016). Briefly, 899 
upon thawing the embryos were transferred to 3 ml of 0.5% sucrose thawing medium and 900 
incubated for 5 min at 37°C, followed by 3 ml of 0.2% sucrose thawing medium for 10 min at 901 
37°C. The embryos were then washed through 7 drops of diluent solution prior to culture. 902 
Human blastocysts were thawed using the Blast thaw kit (Origio; 10542010) following the 903 
manufacturer’s instruction.  904 
 905 
Human and mouse microinjection and culture 906 
Human and mouse embryo microinjections were performed in Global Total media with 907 
HEPES under mineral oil on a heated stage with a holding pipet (Research Instruments) and a 908 
Femtojet 4i microinjection manipulator (Eppendorf) set at approximately 40 injection pressure 909 
and 20 constant pressure. Embryos were microinjected with a mixture of Cas9 910 
mRNA+sgRNA or the ribonulceoprotein complex back-filled into microfilament glass 911 
capillary injection needles (World Precision Instruments; TW100F-6) pulled using a pipet 912 
puller (Suter; P-97 micropipette puller). The microinjection procedure took ~15 min to 913 
complete. 914 
 915 
Human or mouse embryos were cultured in drops of pre-equilibrated Global media 916 
(LifeGlobal; LGGG-20) supplemented with 5 mg/mL protein supplement (LifeGlobal; LGPS-917 
605) and overlaid with mineral oil (Origio; ART-4008-5P). Pre-implantation embryos were 918 
incubated at 37oC and 5.5% CO2 in an EmbryoScope+ time-lapse incubator (Vitrolife) for 919 
either 3 – 4 d (mouse) or 5-6 d (human). 920 
 921 
Evaluating potential off-target sites 922 
Putative off-targets were determined using the MIT CRISPR Design tool (crispr.mit.edu) 923 
which indicated top scoring off-target sites. We evaluated sequences that had mismatches of 924 
less than or equal to 3 nucleotides compared to the sgRNA2b sequence. As described 925 
previously17 potential off-target sites were also identified by using the following parameters: 926 
12 basepairs of the sgRNA seed sequence plus an NGG PAM sequence where (N was varied 927 
to include all possible nucleotides) were searched against the reference human genome 928 
(hg19). 929 
 930 
Genomic DNA extraction 931 
hESCs were lysed using proteinase K digestion (10 g/ml in lysis buffer [100 mM Tris buffer 932 
pH 8.5, 5mM EDTA, 0.2% SDS, 200 mM NaCl]) overnight at 37°C. gDNA was extracted 933 
from the lysed cells using phenol:chloroform extraction followed by ethanol precipitation.  934 
 935 
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Genomic DNA from fixed embryos (human and mouse) was isolated using the alkaline lysis 936 
method; 25 l of 50 mM NaOH was added to the sample and incubated at 95°C for 5 min. 937 
Samples were neutralized by adding 2.5 l of 1M Tris-HCL pH 8.0.  938 
 939 
The Illustra Single Cell GenomiPhi DNA Amplification Kit (GE Healthcare Life Sciences; 940 
29108039) was used according to manufacturer’s instructions to amplify gDNA from 941 
unfixed mouse blastocysts. DNA was purified by adding 30 ul of 20 mM EDTA, 5 µl of 3 M 942 
sodium acetate and 137 µl ice cold ethanol. Tubes were mixed by inverting and centrifuged at 943 
16,000 x g for 20 min.  Supernatant was removed and DNA was washed in 100 µl ice cold 944 
70% ethanol by mixing and centrifuging for 5 min. DNA was resuspended by adding 20 µl 945 
H2O and incubating for 20 min at 4
oC before mixing by gentle pipetting.   946 
 947 
Genomic DNA from single cells microdissected from human embryos was extracted using the 948 
G+T-protocol and amplified using REPLI-g Single Cell Kit (Qiagen; 150343) according to 949 
manufacturer’s guidelines. In preparation for PCR amplification and MiSeq analysis the 950 
WGA-DNA product was diluted 1:100 in nuclease-free water, and 2 µl of this was used as the 951 
template in a reaction containing 25 µl Phusion High Fidelity PCR Master Mix (New England 952 
Biolabs), 2.5 µl 5 µM forward primer, 2.5 µl reverse primer and 18 µl nuclease-free water. 953 
Thermocycling settings used were as follows: 98 oC 30 sec, 35 cycles of 98 oC 10 sec, 58 oC 954 
30 sec, 72 oC 30 sec, and a final extension of 72 oC for 5 min. PCR amplicons were analysed 955 
by Sanger sequencing and indels were quantified by TIDE webtool37. 956 
 957 
On- and off-target sites were amplified using primers listed in Extended Data Fig. 10a using 958 
the GC rich PCR system (Sigma-Aldrich; 12140306001). Primers were designed to generate 959 
amplicons of approximately 250 bp centered around the predicted cute site so as to maximize 960 
the detection of a variety of mutations and ensure that each amplicon was sequenced 961 
continuously from the forward and reverse barcode. We excluded primers that had SNPs 962 
within their sequence so as to prevent allelic drop out. For the time-course genotypic analysis 963 
bulk cells were collected every 24 h and PCR products were amplified from the extraction 964 
genomic DNA. These products were used to generate multiplexed libraries for targeted 965 
amplicon sequencing by MiSeq according to the manufacturer’s instructions (Illumina). 966 
 967 
For gDNA amplified through the G+T-seq protocol, amplicons for genotyping were generated 968 
using Phusion High Fidelity PCR Master Mix (New England Biolabs). Miseq library 969 
preparation, quantification, pooling and denaturation were performed according to the 970 
manufacturer’s instructions (Illumina). For low input samples amplicons were cleaned using 971 
an equal volume of AMPure XP beads according to manufacturer’s instructions (Beckman 972 
Coulter) Index PCR was performed using 10 l of cleaned amplicon, 12.5 l Q5 high fidelity 973 
2X Master Mix (NEB; M0492S), 1.25 l Nextera XT Index 1 primer, 1.25 l Nextera XT 974 
Index 2 primer (Nextera XT Index kit; FC 131 1001). The thermocycling parameters used 975 
were: 98°C for 30 sec, 35 cycles of 98°C for 10 sec, optimized annealing temperature for 30 976 
sec, 72°C for 30 sec, and a final extension of 72°C for 2 min. Index PCR was cleaned using 977 
equal volume of AMPure XP beads as described previously. Beads were rehydrated with 20 978 
l nuclease-free water.  5 l of the index PCR product was run on a gel to identify any 979 
samples with over-abundance of primer dimers, which were subsequently subjected to gel size 980 
selection and extraction using QIAquick gel extraction kit (Qiagen; 28704). Index PCR 981 
products were quantified using QuantiFluor dsDNA system (Promega; E2670). The 982 
concentration was used to determine the dilution required to obtain a 5 M solution of each 983 
sample. 5 l of each sample was pooled and the library was spiked with 20% PhiX genomic 984 
control (Illumina; FC 110 3001). Sequencing generated paired-end (2 x 250 bp) dual indexed 985 
reads. After sequencing, reads were demultiplexed and stored as FASTQ files for downstream 986 
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processing and analysis. The CRISPR Genome Analyser38 or CRISPR Cas Analyser39 tools 987 
were used to align the reads and to determine the percentage of non-wild-type reads resulting 988 
from editing, as well as assessing the position and size of each indel for all of the PCR 989 
amplicons evaluated. 990 
 991 
Digenome sequencing 992 
Digenome-seq was performed as described previously15,16. Briefly, 20 g of genomic DNA 993 
was incubated with pre-incubated 100 nM recombinant Cas9 protein and 300 nM sgRNA in a 994 
reaction volume of 1 ml (100 mM NaCl, 50 mM Tris-HCl, 10 mM MgCl2, 100 μg/ml  BSA, 995 
pH 7.9) at 37 °C for 8 h. Digested DNA was mixed with 50 μg/ml RNase A (Qiagen) at 37 °C 996 
for 30 min, and purified again with a DNeasy Tissue Kit (Qiagen). 1 g of digested DNA was 997 
fragmented using the Covaris system and ligated with adaptors using TruSeq DNA libraries. 998 
DNA libraries were subjected to whole genome sequencing was performed at Macrogen using 999 
an Illumina HiSeq X Ten at a sequencing depth of 30–40X. In vitro DNA cleavage scores 1000 
were calculated using a scoring system described previously16. 1001 
 1002 
Immunohistochemistry 1003 
Embryos and cells were fixed with 4% paraformaldehyde in PBS respectively for 1 h and 1004 
overnight at 4oC and immunofluorescently analysed as described previously2. The primary 1005 
antibodies used are listed in Extended Data Fig. 10b. Embryos were placed on coverslip 1006 
dishes (MatTek) for confocal imaging. 1007 
 1008 
Cytogenetic analysis 1009 
To determine the chromosome copy number, single or multiple blastomeres were biopsied 1010 
from embryos at the cleavage stage and clumps of approximately five cells were 1011 
microdissected from blastocysts. The cells were washed through 3 drops of a wash buffer 1012 
(PBS/0.1% polyvinyl alcohol), which had previously been tested to confirm absence of 1013 
contaminating DNA (Reprogenetics UK). The cells were transferred to 0.2 ml PCR tubes in a 1014 
volume of 1.5 uL, lysed and subjected to whole genome amplification (SurePlex, Rubicon) 1015 
followed by low-pass next generation sequencing (coverage depth <0.1x) (VeriSeq PGS kit, 1016 
Illumina). Libraries were prepared according to the manufacturer’s instructions and sequenced 1017 
using the MiSeq sequencing platform. Typically, ~1 million reads were generated per sample, 1018 
of which 60-70% successfully mapped to unique genomic sites. Mapped reads were 1019 
interpreted using BlueFuse Multi software (Illumina) in order to generate chromosome copy 1020 
number profiles. This strategy has been extensively validated and is widely used for the 1021 
detection of whole chromosome losses and gains, as well as segmental aneuploidy, in human 1022 
embryos undergoing preimplantation genetic diagnosis (PGD)26. Analysis of single 1023 
blastomeres allowed each chromosomal region of at least 5 Mb to be assigned a copy number 1024 
of 0, 1, 2, 3 or 4 (corresponding to nullisomy, monosomy, disomy, trisomy or tetrasomy). In 1025 
trophectoderm samples, composed of several cells, it was also possible to detect the presence 1026 
of chromosomal mosaicism, indicated when copy number values for a given chromosome had 1027 
an intermediate value, between the thresholds for assigning 1 and 2 or 2 and 3 chromosome 1028 
copies40. 1029 
 1030 
Imaging 1031 
Confocal immunofluorescence pictures were taken with a Leica SP5 confocal microscope and 1032 
3 - 5 μm thick optical section were collected. Quantification was performed manually using 1033 
Fiji (ImageJ) or automated using MINS 1.3 software41. 1034 
 1035 
Epifluorescence images were performed on an Olympus IX73 using Cell^F software 1036 
(Olympus Corporation) or on an EVOS FL cell imaging system (AMF4300). Phase contrast 1037 
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images and videos were performed on an Olympus IX73 using with Cell^F software and RI 1038 
Viewer software (Research Instruments), respectively. 1039 
 1040 
Time-lapse imaging was performed using an EmbryoScope+ time-lapse incubator (Vitrolife) 1041 
and annotated using the EmbryoViewer software.  1042 
 1043 
Culture conditions for hESCs and engineering inducible cell lines 1044 
Clonal H9 hESCs (WiCell) (n = 2 or 3 per sgRNA) were cultured in feeder- and serum-free 1045 
conditions either in mTeSR1 (Stem Cell Technologies) on growth factor reduced Matrigel-1046 
coated dishes (BD Biosciences) or as previously described42. Successfully targeted cells were 1047 
selected using 0.25 µg/ml puromycin (Sigma-Aldrich) and 15 µg/ml geneticin (Insight 1048 
biotechnology ltd.) for 3 d prior to induction. Tetracycline hydrochloride (Sigma-Aldrich; 1049 
T7660) was used at 1 µg/ml to induce guide expression. hESCs underwent routine 1050 
mycoplasma screening and katyotyping. 1051 
 1052 
Generation of optimized inducible knockout (OPTiKO) hESC lines 1053 
The sgRNA sequences were cloned into the pAAV-Puro_siKO-TO vector as previously 1054 
described11. Briefly, complementary single stranded oligonucleotides (Extended Data Fig. 1055 
10a) were annealed and scarlessly ligated to AarI-digested plasmids between the H1-TO 1056 
tetracycline-inducible promoters and the scaffold sgRNA sequence. The Cas9 and inducible 1057 
sgRNA targeting vectors were each inserted into one of the two alleles of the AAVS1 locus by 1058 
homologous-directed recombination facilitated by two obligate heterodimer Zinc Finger 1059 
Nucleases (ZFN)11. Cells were cultured in the presence of 10 µM ROCK inhibitor Y-27632 1060 
(Sigma-Aldrich; Y0503) in media without antibiotics 24 h prior to nucleofection. Cells were 1061 
washed with PBS (Life Technologies; 14190-094) and dissociated with Accutase (Life 1062 
Technologies; A11105-01) for 5 min at 37°C. Colonies were mechanically triturated into 1063 
clumps of 2/3 cells and counted. 2x106 cells were nucleofected in 100 μl with a total of 12 μg 1064 
of DNA (4 μg each for the two ZFN plasmids, and 2 μg each for the two targeting vectors) 1065 
using the Lonza P3 Primary Cell 4D-Nucleofector X Kit and the cycle CA-137 on a Lonza 1066 
4D-Nucleofector System. Cells were incubated for 5 min at RT, after which antibiotic-free 1067 
KSR containing 10 µM ROCK inhibitor was added. After another 5 min the cell suspension 1068 
was distributed on pre-plated DR4 (Applied Stem Cell; ASF-1013) drug resistant MEF 1069 
feeders in antibiotic-free KSR media. Four days post nucleofection, cells underwent double 1070 
antibiotic selection with 0.5 µg/ml Puromycin (Sigma-Aldrich) and 25 µg/ml Geneticin (G418 1071 
Sulfate (Gibco)) for 7 days. Targeted colonies appeared after 4-8 d and were mechanically 1072 
picked and clonally expanded at 10-14 d after transfection. 1073 
 1074 
Extensive genotyping was carried out on the targeted clones to check for correct AAVS1 gene 1075 
targeting and to exclude the presence of randomly integrated plasmids, as previously 1076 
described11. Briefly, genomic DNA was extracted using the Wizard Genomic DNA 1077 
Purification Kit (Promega; A1120). Site-specific integration was checked for both 5’and 1078 
3’ends of each of the two targeting vectors (Cas9 and inducible sgRNA). Clones were also 1079 
screened for the absence of the WT locus (indicating homozygous targeting) and for the 1080 
absence of amplicons for both the 5’ and 3’ ends of the targeting vector backbones to ensure 1081 
there was no random integration of the plasmid). 1082 
 1083 
Flow cytometry 1084 
Cells were collected every day for 5 d alongside matched control cells. Cells were dissociated 1085 
into single cell suspension using TrypLE Select 1X (Gibco; 12563011) for 5 min at 37°C. The 1086 
cell suspension was pelleted, washed with PBS (Life Technologies; 14190-094) then fixed 1087 
and permeabilized using BD Cytofix/Cytoperm (554714) for 20 min at 4°C. Perm/wash buffer 1088 
(diluted 1:10 in embryo transfer water) was used for all subsequent antibody and wash steps 1089 
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unless indicated otherwise. After fixation, cells were washed once then stored at 4°C until the 1090 
d5 sample had been collected, at which point all samples underwent intracellular staining. 1091 
Cells were blocked for 30 min at room temperature with perm/wash buffer containing 10% 1092 
donkey serum (Bio-rad; C06SB) and 0.1% Triton X-100 (ThermoFisher Scientific; 85111). 1093 
Cells were stained with primary antibodies by incubating at RT for 1 h and cells were washed 1094 
three times following each incubation. Negative control secondary only stained cells and 1095 
unstained cells were performed on each batch of cells at a given day. Flow cytometry was 1096 
performed using a Cyan ADP flow cytometer and the Summit software (Beckman Coulter), 1097 
and 10,000-50,000 events were recorded. Flow cytometry result analysis was performed using 1098 
FlowJo. Cells were first gated based on forward and side scatter properties, after which 1099 
singlets were isolated based on the relationship between side scatter area peak area and width. 1100 
A secondary only negative control was used to determine the background and OCT4 positive 1101 
cells were quantified relative to cells that were OCT4 negative in the total bulk population of 1102 
cells analysed. 1103 
 1104 
RNA isolation from hESCs for RNA-seq and qRT-PCR 1105 
qRT-PCR data presented in Extended Data Fig. 1c was generated as follows: RNA was 1106 
isolated using TRI reagent (Sigma) and DNase I-treated (Ambion). cDNA was synthesized 1107 
using a Maxima first strand cDNA synthesis kit (Fermentas). qRT-PCR was performed using 1108 
SensiMix SYBR low-ROX kit (Bioline) on a QuantStudio 5 machine (ThermoFisher 1109 
Scientific). Primers pairs used are listed in the Extended Data Fig. 10a. Each sample was run 1110 
in triplicate and samples were normalized using GAPDH as the housekeeping gene and the 1111 
results were analysed using the ΔΔCt method 1112 
 1113 
In preparation for RNA-sequencing of the hESCs induced to express sgRNA2b, samples were 1114 
further cleaned using ethanol precipitation. Libraries were prepared using KAPA mRNA 1115 
HyperPrep kit for Illumina platforms (Roche Sequencing Solutions Inc.) 1116 
 1117 
qRT-PCR data presented in Extended Data Fig. 2b was generated as follows: RNA was 1118 
extracted using the GenElute Mammalian Total RNA Miniprep Kit (Sigma-Aldrich; RTN350-1119 
1KT) and the On-Column DNAse I Digestion kit (Sigma-Aldrich; DNASE70-1SET). 500 ng 1120 
of RNA was reverse transcribed with SuperScript II (Invitrogen; 18064071). qPCR was 1121 
performed using 5 ng of cDNA and SensiMix SYBR low-ROX (Bioline; QT625-20). qRT-1122 
PCR was performed on a Stratagene Mx-3005P (Agilent Technologies) and the results were 1123 
analysed using the ΔΔCt method. Each sample was run in duplicate and samples were 1124 
normalized using RPLP0 as the housekeeping gene. 1125 
 1126 
G&T-seq 1127 
Samples were processed using a previously published protocol that was adapted where 1128 
indicated29. Single cells from microdissected human embryos were picked using 100 μm inner 1129 
diameter Stripper pipette (Origio) and transferred to individual low bind RNAse-free tubes 1130 
containing 2.5 µl RLP plus buffer (Qiagen; 79216).  1131 
 1132 
To separate RNA and genomic DNA (gDNA) 50 µl of Dynabeads were washed and incubated 1133 
with 100 uM biotinylated poly-dT oligonucleotide (IDT). 10 µl of oligo-dT beads were added 1134 
to each tube containing the single cell. Samples were incubated in a thermomixer for 20 min 1135 
at room temperature at 2000 rpm. Tubes were put on a magnet until the beads collected into a 1136 
pellet and the supernatant went clear. The supernatant containing the gDNA was transferred to 1137 
a new collection tube. Beads were washed three times to collect any residual gDNA. 1138 
 1139 
cDNA was generated from the RNA captured on the bead using the SMARTer v4 Ultra Low 1140 
Input kit (Clontech; 634891) as previously described3. Reverse transcription was performed 1141 
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on the thermomixer using the settings 2 min at 42oC at 2,000 rpm, 60 min at 42oC at 1,500 1142 
rpm, 30 min at 50oC at 1,500 rpm and 10 min at 60oC at 1,500 rpm. cDNA was amplified by 1143 
adding 12.5 μl 2X SeqAmp PCR buffer, 0.5 μl PCR Primer II A (12µM), 0.5 µl SeqAmp 1144 
DNA polymerase, 1.5 μl Nuclease free water. Beads were mixed on thermomixer for 60 sec at 1145 
room temperature at 2,000 rpm and then were incubated on a PCR machine using the 1146 
following settings: 95oC for 1 min, 24 cycles of 98oC for 10 sec, 65oC for 30 sec and 68oC for 1147 
3 min, before a final extension for 10 min at 72oC. Amplified cDNA was purified by adding 1148 
25 μl Ampure XP beads according to manufacturer’s instructions. 12 µl of purification buffer 1149 
was added to rehydrate the pellet and incubated for 2 min at room temperature. cDNA was 1150 
eluted by pipetting up and down 10 times before returning the tube to the magnet. The clear 1151 
supernatant containing the cDNA was removed from the immobilised beads and transferred to 1152 
a new low-bind tube. cDNA was stored at -80°C until library preparation. cDNA quality was 1153 
assessed by High Sensitivity DNA assay on an Agilent 2100 Bioanalyser with good quality 1154 
cDNA showing a broad peak from 300 to 9,000 bp. cDNA concentration was measured using 1155 
QuBit dsDNA HS kit (Life Technologies). 1156 
 1157 
In preparation for library generation cDNA was sheared using an E220 focused-ultrasonicator 1158 
(Covaris) to achieve cDNA in 200-500 bp range. 10 μl of cDNA sample and 32 μl purification 1159 
buffer was added to Covaris AFA Fiber Pre-Slit Snap Cap microTUBE. cDNA was sheared 1160 
using the following settings: Peak Incident power 175 W, Duty Factor 10%, 200 cycles per 1161 
burst, water level 5.  1162 
 1163 
Libraries were prepared using Low Input Library Prep Kit v2 (Clontech; 634899) according to 1164 
manufacturer’s instructions. Dual indexing was performed by substituting the manufacturer’s 1165 
provided indexing adaptors with NEBNext Multiplex Oligos for Illumina Dual Index primers 1166 
set 1 (NEB; E7600S). Library quality was assessed by Bioanalyser and the concentration was 1167 
measured by high sensitivity QuBit assay.  1168 
 1169 
25 µl of AMPure beads was added to each collection tube containing the gDNA. Tubes were 1170 
mixed well and incubated at room temperature for 20 min so that the DNA could be bound to 1171 
the beads. Tubes were put on the magnet until the supernatant ran clear so that it could be 1172 
removed and discarded. The beads were washed twice with 100 µl 80% ethanol. Any 1173 
remaining ethanol was removed and beads allowed to dry. 1174 
 1175 
Genotyping cells from human embryos 1176 
PCR amplification of the sgRNA2b on-target site was initially performed on all samples using 1177 
a primer pair generating an amplicon size of 244 bp suitable for MiSeq analysis. Any samples 1178 
which failed three times to amplify using this primer pair were subjected to amplification 1179 
using alternative primer pairs listed in Extended Data Fig. 10a. Putative off-target sites were 1180 
evaluated using the primer pairs listed in Extended Data Fig. 10a. 1181 
 1182 
Single-cell RNA-seq data analysis 1183 
RNA-Seq data of single cells were obtained as paired-end reads and analysis was performed 1184 
blinded to the identity of the samples. The RNA-Seq data flow was managed by a GNU make 1185 
pipeline. Transcript reads were aligned to the Ensembl GRCh37 genome using Tophat2 1186 
(version 2.1.1 with option no coverage search)43; alignment rates were typically between 60-1187 
80%. Transcript counts were computed using the featureCounts program (version 1.5.1)44. A 1188 
quality filter was applied to the matrix, ensuring >50000 total transcript reads per cell and >5 1189 
reads in at least 5 samples. The raw transcript counts were corrected for read-count depth 1190 
effects using the SCnorm package45 single-group design matrix. The RUVSeq46 (version 1191 
1.10.0) (Risso et al. 2014) was used for between-sample normalisation by applying the 1192 
'betweenLaneNormalization' function with 'full' quantile regression. For PCA analysis, 1193 
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transcript counts were transformed using a asinh(x/2) transformation with per-gene centering 1194 
to obtain near-Gaussian and zero-centred count distributions. The prcomp function of the stats 1195 
package in R (version 3.4.1) was applied to the count matrix and single cells were projected 1196 
into the plane of the first two eigenvectors. 1197 
 1198 
Independently, sequenced reads from all single cell samples were also aligned to the human 1199 
reference genome sequence GRCh38 using TopHat2 (version 2.1.1)43 and parameters were 1200 
optimised for 100bp paired-end reads. Read counts per gene were calculated using the python 1201 
package HTSeq (version 0.6.1)47 and differential gene expression analysis was carried out 1202 
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